Stockscreener 앱 받기
4.89
0.46%
-0.03
전일 마감가:
$4.92
열려 있는:
$4.9
하루 거래량:
726.10K
Relative Volume:
0.19
시가총액:
$479.15M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-1.86%
1개월 성능:
-14.23%
6개월 성능:
+13.37%
1년 성능:
+160.50%
1일 변동 폭
$4.82
$4.99
1주일 범위
$4.58
$5.027
52주 변동 폭
$1.67
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
명칭
Atyr Pharma Inc
전화
(858) 731-8389
주소
10240 SORRENTO VALLEY ROAD, SAN DIEGO
ATYR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
4.89 | 481.11M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.00 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.39 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.44 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
667.01 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.57 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-18 | 개시 | Leerink Partners | Outperform |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-04 | 개시 | Wells Fargo | Overweight |
| 2024-09-05 | 개시 | Jefferies | Buy |
| 2023-07-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-10-12 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-10 | 개시 | Laidlaw | Buy |
| 2020-08-17 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 개시 | ROTH Capital | Buy |
| 2020-03-02 | 개시 | Oppenheimer | Outperform |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-07 | 개시 | Piper Jaffray | Overweight |
| 2016-12-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-12-16 | 개시 | Citigroup | Neutral |
| 2015-06-01 | 개시 | Citigroup | Buy |
| 2015-06-01 | 개시 | JP Morgan | Overweight |
모두보기
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
What institutional flow reveals about aTyr Pharma Inc.Long Setup & Weekly High Return Stock Opportunities - Newser
How to track smart money flows in aTyr Pharma Inc.Weekly Profit Summary & Risk Managed Investment Entry Signals - Newser
Is it too late to sell aTyr Pharma Inc.Risk Management & Real-Time Buy Signal Alerts - Newser
How to use a screener to detect aTyr Pharma Inc. breakoutsQuarterly Earnings Report & Technical Entry and Exit Alerts - Newser
Moving Average Crossover Confirms Uptrend in aTyr Pharma Inc.2025 Bull vs Bear & Stepwise Trade Execution Plans - beatles.ru
aTyr Pharma Inc.’s volatility index tracking explainedJuly 2025 Pullbacks & Weekly Chart Analysis and Guides - Newser
ATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations - Yahoo Finance
Live market analysis of aTyr Pharma Inc.Gold Moves & Free Safe Capital Growth Stock Tips - Newser
Is aTyr Pharma Inc. stock bottoming outBreakout Watch & Free Growth Oriented Trading Recommendations - Newser
Analyzing drawdowns of aTyr Pharma Inc. with statistical tools2025 Valuation Update & Real-Time Stock Movement Alerts - Newser
What makes aTyr Pharma Inc. stock price move sharplyNew Guidance & High Return Stock Watch Alerts - beatles.ru
Technical analysis overview for aTyr Pharma Inc. stockQuarterly Profit Review & AI Based Buy and Sell Signals - Newser
Developing predictive dashboards with aTyr Pharma Inc. dataEarnings Risk Summary & Real-Time Price Movement Reports - Newser
High Growth US Tech Stocks To Watch In August 2025 - Yahoo Finance
RSI Crosses Above 30 for aTyr Pharma Inc. — Reversal in SightTrade Analysis Summary & Daily Stock Trend Reports - beatles.ru
Regression analysis insights on aTyr Pharma Inc. performanceEarnings Risk Report & AI Driven Stock Reports - Newser
aTyr Pharma: Estimating Their Phase 3 Lung Disease Trial Outcome (NASDAQ:ATYR) - Seeking Alpha
Does aTyr Pharma Inc. qualify in momentum factor screeningMarket Activity Summary & Weekly High Return Stock Forecasts - Newser
Risk adjusted return profile for aTyr Pharma Inc. analyzed2025 Key Lessons & Breakout Confirmation Alerts - Newser
Heatmap analysis for aTyr Pharma Inc. and competitorsWeekly Trade Review & Verified Short-Term Plans - Newser
Is aTyr Pharma Inc. a play on infrastructure spendingDividend Hike & Daily Growth Stock Tips - newsimpact.co.kr
Applying Elliott Wave Theory to aTyr Pharma Inc.Weekly Gains Report & Risk Adjusted Buy/Sell Alerts - Newser
How to escape a deep drawdown in aTyr Pharma Inc.2025 Year in Review & Short-Term Trading Opportunity Alerts - Newser
Can machine learning forecast aTyr Pharma Inc. recoveryIndex Update & AI Forecasted Entry and Exit Points - Newser
Is aTyr Pharma Inc. exposed to currency risksTrend Reversal & AI Enhanced Trade Execution Alerts - thegnnews.com
XTX Topco Ltd Has $59,000 Stock Holdings in aTyr Pharma, Inc. (NASDAQ:ATYR) - Defense World
Trendlines Suggest aTyr Pharma Inc. May Bottom Out SoonTechnical Breakout Signal Plan Strategy - beatles.ru
Optimistic Outlook for aTyr Pharma Amidst Controversies: Analyst Highlights Potential in EFZO-FIT Study - TipRanks
Custom Dashboard Highlights aTyr Pharma Inc. Price MomentumEarnings Miss & Free Growth Oriented Trading Recommendations - sundaytimes.kr
aTyr Pharma Inc. Shows Support at Fibonacci LevelJuly 2025 EndofMonth & Fast Moving Market Watchlists - newsyoung.net
Published on: 2025-08-14 00:58:46 - Newser
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), Cullinan Management (CGEM) and aTyr Pharma (ATYR) - The Globe and Mail
Will aTyr Pharma Inc. Bounce From 52 Week LowPotential Breakout Stock List Published This Week - sundaytimes.kr
ATYR.O Plummets 7.8%: A Deep Dive into the Unusual Intraday Move - AInvest
aTyr Pharma Inc. Outperforms Peers on Volume MetricsSwing Setup With Technical Confirmation Explained - 선데이타임즈
Optimistic Buy Rating for aTyr Pharma Amid Promising Phase 3 Data and Innovative Sarcoidosis Treatment Approach - TipRanks
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of “Buy” by Brokerages - Defense World
aTyr Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Traders Consider Averaging Down in aTyr Pharma Inc.Entry Alert Based on Volume Spikes Detected - metal.it
Promising Developments and Strong Financial Position Drive Buy Rating for aTyr Pharma - TipRanks
1 Small-Cap Biotech Stock Poised for a Breakout - AOL.com
Connect Biopharma Holdings Limited shares rise 1.93% intraday after aTyr Pharma announced Phase 3 EFZO-FIT™ study completion. - AInvest
aTyr Pharma Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
3 Innovation Stocks With Parabolic Upside Potential - AOL.com
Atyr Pharma: Q2 Earnings Snapshot - Connecticut Post
aTyr Pharma Reports Q2 2025 Financial Results - TipRanks
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update - GlobeNewswire
aTyr Pharma reports Q2 EPS (22c), consensus (18c) - TipRanks
ATYR Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Atyr Pharma Inc (ATYR) 재무 분석
Atyr Pharma Inc (ATYR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Atyr Pharma Inc 주식 (ATYR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
1.17%
0.36%
자본화:
|
볼륨(24시간):